We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Tecentriq “continues to demonstrate benefits across multiple cancer types and therefore remains a meaningful treatment option for many patients,” Roche said. Read More
“While we are disappointed that BRII-196 and BRII-198 have not shown clear benefits during the interim analysis … we remain committed to investigating this antibody combination in ambulatory COVID-19 patients through the ongoing ACTIV-2 trial,” said Brii Biosciences CEO Zhi Hong. Read More
The test showed it could detect a SARS-CoV-2 T cell mediated immune response in patients who tested positive for coronavirus, even when they had negative serology test results for antibodies. Read More
According to Lilly, tirzepatide reduced blood sugar levels by 2.09 percent at 5 mg, 2.37 percent at 10 mg and 2.46 percent at 15 mg, vs. 1.86 percent for 1 mg of Ozempic. Read More
The Valencia, Spain-based company said qp-Prostate is the only technology available that offers automatic regional organ segmentation that can help reduce interpretation time by identifying and segmenting each prostate region. Read More
“While we are disappointed with the recommendation … We are encouraged by the safety profile of VIR-7831 and by the possibility of a benefit on top of remdesivir and corticosteroids in this advanced cohort of patients,” said Vir Biotechnology CEO George Scangos. Read More